(PYM) Phytopharm
Summary
|
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||
| Headline | Source | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mon 09:25 | RNS |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
RNS Number : 8480W Phytopharm PLC 06 February 2012 Phytopharm plc
Annual Information Update Phytopharm plc (the Company) announces that, in accordance with the requirements of Prospectus Rule 5.2 issued by the Financial Services Authority, and following publication of the Annual Report on 6 February 2012, the following information has been published or made available to the public between 8 February 2011 and 6 February 2012 inclusive, in compliance with laws and rules dealing with the regulation of securities, issuers of securities and securities markets. 1. Announcements made via the Regulatory Information Service ("RIS") All the announcements listed below were published through a regulatory information service on the dates indicated. Copies can be obtained from the London Stock Exchange website, http://www.londonstockexchange.com or from the Company's website www.phytopharm.com
2. Documents published or sent to Shareholders or submitted to the FSA including those filed with the National Storage Mechanism:
The 2011 Interim and 2011 Annual reports are available on the Company's website www.phytopharm.com 3. Documents filed at Companies House The following documents were files at Companies House. Copies of these documents can be obtained from the Companies House website at www.companieshouse.gov.uk, or Companies House, Crown Way, Cardiff CF14 3UZ
Copies of all documents referred to above are also available for inspection at the Company's registered office (Lakeview House, 2 Lakeview Court, Ermine Business Park, Huntingdon, Cambridgeshire PE29 6UA, United Kingdom) during normal business hours or by written request from the Company Secretary. This annual information is required by, and is being made pursuant to, Article 10 of the Prospectus Directive as implemented by the UK Prospectus Rule 5.2 and not for any other purpose and neither the Company, nor any other person, takes any responsibility for, or makes any representation, express of implied, as to the accuracy or completeness of, the information which it contains. The information is not necessarily up to date as at the date of this annual information update and the Company does not undertake any obligation to update any such information in the future. Neither this annual information update, not referred to in it, constitutes, by virtue of this communication, an offer of securities addressed to any person and it should not be relied on by any person. For further information, please contact: Zoe McGowan, Company Secretary Phytopharm plc Tel No: +44 (0)1480 437697 Further information about Phytopharm can be found on the Company's website www.phytopharm.com This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thu 07:00 | RNS |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
RNS Number : 6151W Phytopharm PLC 02 February 2012
2 February 2012
Phytopharm plc Appointment of Non-Executive Director
Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm" or the "Company") today announces the appointment with immediate effect of Dr Ian Tulloch, former Global Product Marketing Director at Novartis Pharma AG, as a Non-Executive Board Director of Phytopharm. Dr Tulloch will succeed Mr Sandy Morrison, who will step down as a Non-Executive Board Director. Dr Tulloch has over 30 years' experience in the pharmaceutical industry, encompassing a range of senior roles in both research and development and commercial functions. Dr Tulloch has a strong background in neuroscience and has been closely involved in the commercialisation of innovative products for the treatment of Parkinson's disease, depression, epilepsy, multiple sclerosis and pain. From 2002 to 2010 Dr Tulloch was Global Marketing Director for the Neuroscience and Ophthalmic Business Franchise at Novartis AG. Prior to this he held global medical marketing positions at GlaxoSmithKline/SmithKline Beecham between 1990 and 2002 and was Drug Discovery Programme Director at Reckitt Benckiser from 1978 to 1990. Dr Tulloch has a BSc (Hons) in Pharmacology and a PhD in Neuropharmacology, both from the University of Edinburgh. The appointment of Dr Tulloch is part of the Board's succession planning process. Accordingly, Mr Sandy Morrison will step down from the board following the Company's Annual General Meeting, which will be held before 31 March 2012. Mr Alistair Taylor, Chairman, commented, "I am delighted to welcome Ian to Phytopharm. His vast commercial expertise, particularly in the field of neuroscience and ophthalmology, will significantly contribute to our business development efforts and strengthen the Board as we move closer to obtaining the results from our clinical study in Parkinson's disease." "I'd like to thank Sandy for the substantial contribution he has made to Phytopharm as a board member since 2006 and particularly in the period as interim CEO, during which he steadily guided the company through a period of strategic reprioritisation. We wish him well as he pursues new areas of interest." There are no disclosures to be made under paragraphs 9.6.13R of the Listing Rules in respect of Dr Tulloch.
About Phytopharm Phytopharm is a development stage pharmaceutical company developing novel treatments targeting diseases with high levels of unmet need. Our lead series of compounds, the sapogenins (including Cogane™ and Myogane™), has the potential to be a new class of therapy for neurodegenerative diseases including Parkinson's disease, ALS and glaucoma. Phytopharm operates as a virtual company ensuring the majority of our financial resources are focused on our pharmaceutical pipeline. We utilise a network of scientific and clinical experts to help guide our development projects with our experienced pharmaceutical managers overseeing operations. Our commercially focused development projects have the potential to produce significant treatment advances in our target areas of neurodegeneration and inflammatory disease. Our products are single chemical entities with novel mechanisms of action protected by strong patent families. Phytopharm is listed on the Official List of the London Stock Exchange. Further information on Phytopharm is available from the Company's website www.phytopharm.com Forward-looking statements Certain information included in these statements is forward‑looking and involves risk and uncertainties that could cause results to differ materially from those expressed or implied by the forward looking statements. Forward‑looking statements include, without limitation, projections relating to results of operations and financial conditions, market estimates, the Company's plans and objectives for future operations, including future revenues, financial plans and expected expenditures and divestments. All forward‑looking statements in this report are based upon information known to the Company on the date of this announcement. The Company undertakes no obligation to publicly update or revise any forward‑looking statement, whether as a result of new information, future events or otherwise. It is not reasonably possible to itemise all of the many factors and specific events that could cause the Company's forward‑looking statements to be incorrect or that could otherwise have a material adverse effect on the future operations or results of the Company.
This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 27-01-12 | RNS |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
RNS Number : 2981W Phytopharm PLC 27 January 2012 Phytopharm plc 27 January 2012 Posting of Annual Report Phytopharm plc announces that it has published its Annual Report and Accounts 2011. Copies of the Annual Report and Accounts 2011 will shortly be available to view on the Company's website at www.phytopharm.com Hard copies of the Annual Report and Accounts 2011 have been sent to those shareholders who have elected to continue to receive paper communications. A copy has also been filed with the UKLA's National Storage Mechanism and will be available for inspection at www.hemscott.com/nsm.do The unaudited Preliminary Results for the year ended 30 September 2011 were announced on 24 November 2011. The information contained in Appendix 1 (Principal Risks and Uncertainties) and Appendix 2 (Statement of Directors' Responsibilities), which is extracted from the Annual Report and Accounts 2011, is also included in the announcement for the sole purpose of complying with Rule 6.3.5 of the Disclosure and Transparency Rules of the UK Financial Services Authority. Page numbers and cross-references in the extracted information refer to page numbers and cross-references in the Annual Report and Accounts 2011. Zoe McGowan Appendix 1 The nature of pharmaceutical development is such that there are significant inherent risks due to the long and complex development process. Below are those principal risks and uncertainties that the Board considers could have a material impact on the Group's operational results, financial condition and prospects. These risks are not in any particular order of priority and there may be other risks that are either currently unknown or not considered material which could have a similar impact on the Group's business in the future. The Board reviews each area of the business at least annually to identify material risks and the controls in place to manage these risks. Industry risk In common with other research and development stage businesses, Phytopharm's business risks relate principally to the success of its development programmes and to the need to fund its operations through these. The success of the Group's programmes depends upon the quality of the design and the implementation of each programme. The progress of the development programmes therefore represents the best indicator of the Group's performance. A full review of the programmes is given in the Business Review on pages 8 to 12. Financial risk The Group expects to continue to make losses until it is able to increase its revenues sufficiently. Additional funds such as charitable income, collaboration deals and/or further financing may be required to allow further scope for product development. The availability and timing of such additional external funds represent a material uncertainty, although the Group currently has sufficient funds to finance its operational activities for at least the next twelve months. Clinical and regulatory risk Successful commercialisation of the Group's products is likely to depend on successful progress through clinical studies and registration. Development of product candidates involves a lengthy and complex process, and products may not meet the necessary requirements in terms of toxicity, efficacy or safety, or the relevant regulators may not agree with the conclusions of the Group's research and may require further testing or withhold approval altogether. Competition risk The Group's success depends on acceptance of the Group's products by the markets, including physicians and third party payers, and consequently the Group's progress may be adversely affected if it is unable to achieve market acceptance of its products. Factors which may affect the rate and level of market acceptance of any of the Group's products include the existence or entry on to the market of superior competing products or therapies and the price of the Group's products compared to competing products and overall cost effectiveness of the product. Intellectual property risk The Group's success depends in part on its ability to obtain and maintain protection for its intellectual and proprietary information, so that it can stop others from making, using or selling its inventions or proprietary rights. The Group's patent applications may not be granted and its existing patent rights may be successfully challenged and revoked. Counterparty risk The Group relies on third party organisations to conduct its clinical trials and to manufacture its products. If the relationship with, or performance of, any of these partners is adversely affected, the Group's results or operations may be adversely impacted. The Group also derives revenue or financial support from its collaborators and expects to derive additional support from partnering with certain charitable organisations. If these relationships are adversely affected, or if the products involved fail to continue to make satisfactory progress, the Group's results or operations may be adversely impacted. Foreign exchange risk The Group records its transactions and prepares its financial statements in sterling. Where possible the Group maintains natural hedges by matching foreign currency income with foreign currency expenditure. The Group incurs expenditure in foreign currency relating principally to clinical trials which may exceed any revenues in foreign currencies. To the extent that income and expenditure in foreign currencies are not matched, fluctuations in exchange rates between sterling and foreign currencies, principally USD and EUR, may result in realised or unrealised foreign exchange gains and losses. Where there is certainty of the amount and timing of expenditure of foreign currencies, the Group may purchase financial instruments to minimise any foreign exchange gains or losses. Where the timing and / or the amount to be received is uncertain, risk management is more difficult and the Group will use financial instruments wherever possible. To the extent that financial instruments are not utilised, any fluctuations in foreign exchange movements may have a material adverse impact on the results from operating activities. Appendix 2 The Directors are responsible for preparing the Annual Report, the Directors' Remuneration Report and the financial statements in accordance with applicable law and regulations. Company law requires the Directors to prepare financial statements for each financial year. Under that law the Directors have elected to prepare the Group and parent company financial statements in accordance with International Financial Reporting Standards ("IFRSs") as adopted by the European Union ("EU"). Under company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Group and the Company and of the profit or loss of the Group for that period. In preparing these financial statements, the Directors are required to: · select suitable accounting policies and then apply them consistently; · make judgements and accounting estimates that are reasonable and prudent; and · state whether applicable IFRSs as adopted by the EU have been followed, subject to any material departures disclosed and explained in the financial statements. The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and the Group and enable them to ensure that the financial statements and the Directors' Remuneration Report comply with the Companies Act 2006 and, as regards the Group financial statements, Article 4 of the IAS Regulation. They are also responsible for safeguarding the assets of the Company and the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. The Directors are responsible for the maintenance and integrity of the Company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions. Each of the Directors, whose names and functions are listed in the Board of Directors on page 17, confirm that, to the best of their knowledge: · the Group's financial statements, which have been prepared in accordance with IFRSs as adopted by the EU, give a true and fair view of the assets, liabilities, financial position and loss of the Group; and · the information contained in the Directors' Report and the Business Review includes a fair review of the development and performance of the business and the position of the Group, together with a description of the principal risks and uncertainties that it faces. This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 16-01-12 | RNS |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
RNS Number : 5810V Phytopharm PLC 16 January 2012 16 January 2012
Phytopharm plc Cogane™ demonstrates positive results in Amyotrophic Lateral Sclerosis study
Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm" or the "Company") today announces preliminary data indicating that Cogane™ has demonstrated efficacy in a genetic preclinical model of amyotrophic lateral sclerosis (ALS).
The study was performed in a model that has a mutation in the SOD1 gene (SOD1G93A); mutation of the SOD1 gene is a known cause of ALS in humans. In this study Cogane™ was administered orally for 50 days, commencing after ALS‑type symptoms were manifest. This is therefore considered to be a model of severe, late-stage ALS.
Main findings:
· Administration of Cogane™ resulted in a 30‑50% improvement in muscle strength in one muscle type compared to both the untreated control group and a group treated with riluzole (currently the only product marketed for the treatment of ALS). · Treatment with CoganeTM also resulted in an increase in the number of motor units (a measure of functional motor neurones) compared with both the untreated and riluzole treated control groups. · Treatment effects were less clear in a second muscle type which was more severely damaged in the model, though the group treated with Cogane™ again showed an improvement in strength compared to the riluzole treated group.
These are preliminary, headline results and the full results from the study, including histopathology data, will be published in due course.
These results support those reported previously by Phytopharm in which Cogane™ showed benefit in an environmental (toxin-induced) model of ALS, in a progressive motor neuropathy model and in a nerve crush model. Collectively the results from these four different models of ALS provide strong support for the utility of Cogane™ in the treatment of this condition.
ALS, also known as Lou Gehrig's disease, is the most common form of motor neurone disease, a neurodegenerative disease with limited treatment options and poor prognosis. It is characterised by progressive loss of both lower (spinal cord and brain stem) and upper (cerebral cortex) motor neurones, which leads to severe muscle weakness and wasting, followed by paralysis and death, generally caused by respiratory failure. There is an urgent need for the development of new approaches to this devastating condition.
Phytopharm has obtained orphan drug status in Europe and the US for Cogane™ in ALS.
This study was performed by the group of Professor Linda Greensmith, University College, London, with the financial support of the Motor Neurone Disease Association, a UK based charitable organisation.
Professor Greensmith commented, "The data from this genetic model of ALS are very encouraging and, taken with the data from the other models of ALS in which it has been tested, indicate that Cogane has significant potential as a therapy for ALS and merits further evaluation."
Mr Tim Sharpington, CEO, Phytopharm, said, "These results are very encouraging as we set a difficult challenge in this study by looking for efficacy in a severe, end-stage disease model. We have established an impressive set of data for CoganeTM in a broad range of neurodegenerative disease models, including Parkinson's and Alzheimer's disease as well as ALS. There is a major unmet need and substantial commercial opportunity for new therapies which can delay or halt the progression of these diseases. We look forward to receiving more data on Cogane™ as we complete our ongoing clinical study in Parkinson's disease."
About Phytopharm Phytopharm is a development stage pharmaceutical company developing novel treatments targeting diseases with high levels of unmet need. Our lead series of compounds, the sapogenins (including Cogane™ and Myogane™), has the potential to be a new class of therapy for neurodegenerative diseases including Parkinson's disease, ALS and glaucoma.
Phytopharm operates as a virtual company ensuring the majority of our financial resources are focused on our pharmaceutical pipeline. We utilise a network of scientific and clinical experts to help guide our development projects with our experienced pharmaceutical managers overseeing operations.
Our commercially focused development projects have the potential to produce significant treatment advances in our target areas of neurodegeneration and inflammatory disease. Our products are single chemical entities with novel mechanisms of action protected by strong patent families.
Phytopharm is listed on the Official List of the London Stock Exchange. Further information on Phytopharm is available from the Company's website www.phytopharm.com
About Cogane™ Phytopharm's lead development candidate is Cogane™, a member of the sapogenin class of compounds. It is an orally bioavailable neurotrophic factor modulator that readily crosses the blood‑brain barrier. Cogane™ has demonstrated neuroprotective effects in a range of preclinical models of neurodegenerative diseases. Specifically, CoganeTM has been shown to induce and modulate the production of neurotrophic factors. The neuroprotective and neurotrophic actions of Cogane™ suggest potential beneficial effects in a range of neurodegenerative diseases, including ALS and Parkinson's disease.
Cogane™ has completed long term toxicology studies, has been formulated as a once daily, orally administered therapy and has completed Phase I studies demonstrating a good bioavailability and safety profile.
In addition to the preclinical programme in ALS, Cogane™ is being studied in an ongoing 28 week Phase II trial of early stage Parkinson's disease (CONFIDENT‑PD).
In 2011 Cogane™ was granted Orphan Drug status by both the European Commission and by the US Food & Drug Administration for development in ALS. Orphan status allows significant access to the regulatory authorities for advice and expedited clinical progression as well as providing financial advantages.
About amyotrophic lateral sclerosis (ALS) ALS, also known as Lou Gehrig's disease, is the most prevalent form of motor neurone disease, which generally strikes people between 40 and 60 years of age. It is estimated that there are over 30,000 patients living with ALS in the seven major markets.
About the SOD1G93A rodent model SOD1 (superoxide dismutase 1) gene is responsible for generation of the superoxide dismutase‑1 enzyme. This enzyme helps in the control of free radicals. Mutation of this gene can result in the development of ALS. Although a genetic cause has not been identified in many patients with ALS, approximately 5% have a genetic mutation of the SOD1 gene. The SOD1 rodent model is the most widely studied ALS model.
Forward-looking statements Certain information included in these statements is forward‑looking and involves risk and uncertainties that could cause results to differ materially from those expressed or implied by the forward looking statements.
Forward‑looking statements include, without limitation, projections relating to results of operations and financial conditions, market estimates, the Company's plans and objectives for future operations, including future revenues, financial plans and expected expenditures and divestments. All forward‑looking statements in this report are based upon information known to the Company on the date of this announcement. The Company undertakes no obligation to publicly update or revise any forward‑looking statement, whether as a result of new information, future events or otherwise.
It is not reasonably possible to itemise all of the many factors and specific events that could cause the Company's forward‑looking statements to be incorrect or that could otherwise have a material adverse effect on the future operations or results of the Company.
This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Result Pages: 1 | ||||
| Date/Time | Subject | Author | ||
|---|---|---|---|---|
| Mon 09:28 | ||||
|
|
||||
|
|
||||
|
Annual Information Update
Date : 06/02/2012 @ 09:25 Source : UK Regulatory (RNS & others) Stock : Phytopharm (PYM) Quote : 9.05 -0.05 (-0.55%) @ 08:16 http://bit.ly/AkCRMI |
||||
| 23-01-12 | ||||
|
|
||||
|
|
||||
|
What a cracking little stock to hold.....and so far under the radar, it's just not true!!
Look forward to Aprils glaucoma results! |
||||
| 23-01-12 |
2
|
|||
|
|
||||
|
|
||||
|
One interesting point they brought out in this was at September 2011 it had more cash than the company value.Of course they are spending it but I do think if you are prepared to take a risk they are a buy. There are several disease applications plus promising study data, the disease charities arent mugs and they are backing it. According to this research report and to my own knowlege there isnt any other medication that shows promise to actually be neuroprotective. I hadnt realised the 56% Invesco holding - is there any potential downside of that for the private investor?
|
||||
| 23-01-12 |
2
|
|||
|
|
||||
|
|
||||
|
Phytopharm - Backing for dual strategy
Mon, Jan 23, 2012 at 1:03 PM Click for report http://bit.ly/yip9Da |
||||
|
|
||||
They have not been approved or issued by Interactive Investor Trading Limited.
Editor's Pick:
Stock to Watch: Imperial TobaccoEditor's Pick:
Markets: FTSE 100 uncertain on TuesdayEditor's Pick:
George Godber’s AIM stock picksEditor's Pick:
How to pay less tax on your investmentsEditor's Pick:
Hybridan's Small Cap Wrap
Share
